Ryman Healthcare (RYM) investor relations material

Opening remarks and agenda

• Chair welcomed shareholders in Auckland and online, outlined housekeeping, confirmed quorum, and set the meeting's focus on business reset, financial performance, and strategic direction.

• Agenda included business progress, CEO's performance and strategy update, formal resolutions, and Q&A.

Financial performance review

• Achieved material improvement in operating profitability, cost reductions, and first positive free cash flow in over a decade.

• FY26 saw NZD 188.3 million positive free cash flow, operating EBITDAF of NZD 88.3 million (+94%), and loss before tax per share reduced by 87%.

• Completed NZD 150 million retail bond offer, reinforcing funding strength and flexibility.

• Balance sheet strengthened with no bank debt maturities until FY31 and lowest industry gearing at 27.8%.

• Set FY29 targets: NZD 150 million sustainable cash flow improvement and NZD 500 million balance sheet cash release.

Board and executive committee updates

• Significant board renewal over three years, with multiple new non-executive directors joining between 2023 and 2026, bringing skills in governance, customer, digital, and capital markets.

• Paula Jeffs retiring; Hamish Rumbold appointed, bringing digital and operational expertise.

• Directors Dean Hamilton, James Miller, and Hamish Rumbold stood for re-election and addressed their backgrounds and commitment.